FULL PROGRAM
As at 20.05.2013 – subject to change
Day 1: Friday 2 August
Session 1: Introductory Session
Mark Schembri:The bacterial armamentarium: why Gram negative bacilli are so evil
Yohei Doi:What does multiresistance actually mean?
David Paterson:Mechanisms of resistance made simple and fun: Beta-lactamases
Anton Peleg:Mechanisms of resistance made simple and fun: Resistance to other classes
John Turnidge: The extent of resistance in Asia/Pacific
Session 2: How did we get into this mess?
Ben Rogers:Are animals to blame?
Josh Freeman:Are the airlines to blame?
Krispin Hajkowicz:Are doctors to blame?
David Grolman:Are drug companies to blame?
Paul Ingram:Are nursing homes to blame?
Session 3: Round Table- How are we going to prevent a catastrophe?
Participants: David Looke, Graeme Nimmo, Anthony Allworth, Matthew Cooper, Joe McCormack, Susan Benson
Session 4. Microbiology – Parallel session
John Turnidge: Update from EUCAST and CLSI
Anton Peleg:Beta-lactamase production below the breakpoint: is it clinically significant?
Sanmarie Schlebusch:Rapid Identification and Resistance assessment: The future is mass spectrometry
Jon Iredell:Rapid Identification and Resistance assessment: The future is molecular diagnostics
Paul Ingram:Screening for carbapenem resistant organisms in rectal swabs
Kate McCarthy: Practical experience with the NP test for carbapenemase production
Session 5: Infection Control – Parallel session
Krispin Hajkowicz:Antibiotic Stewards: Partners in Infection Control
Brett Mitchell:The hospital environment as a source of resistant Gram negatives
Josh Freeman:Should all patients with MDR Gram negatives be in contact isolation?
Round-table panel discussion: What would you do with this case?
Facilitator: Megan Reilly
John Ferguson: Recommendations for the Control of Multidrug resistant Gram negatives
Day 2: Friday 3 August
Session 6: In a Bad Place
David Whiley:XDR Gonococcus
Anna Tai:MDR Gram negatives in Cystic fibrosis
Deborah Williamson:TRUS biopsy related sepsis
Julia Clark:MDR Gram negatives in Children
Session 7: Treating seriously ill patients in ICU
Roger Nation:Colistin – How should it be dosed for the critically ill?
Jeff Lipman:The importance of augmented renal clearance of antibiotics
Jason Roberts:Should we be performing therapeutic drug monitoring in seriously ill patients with Gram negative infections?
Joel Dulhunty:Are continuous infusions of beta-lactam antibiotics useful? Results of the BLING RCT
Johan Mouton: How to clinically apply PK/PD principles in critically ill patients to prevent resistance
Anand Kumar: When is single Gram negative cover appropriate for critically ill patients?
Session 8: Treatment: Old and new options
Eugene Athan:Fosfomycin, tigecycline, temocillin and pivmecillinam
David Paterson:New beta-lactams and new beta-lactamase inhibitors
Yohei Doi:New aminoglycosides
Matthew Cooper:Using your imagination to design new antibiotics
Session 9: Treatment of Problem organisms
Kate McCarthy:Pseudomonas aeruginosa
David Paterson:Carbapenem resistant Enterobacteriaceae
Yohei Doi:Acinetobacter
Iain Abbott:TMP/SMX resistant Stenotrophomonas, Achromobacter and Burkholderia
Session 10: Special lecture.
Bart Currie: Treatment of Burkholderia pseudomallei
Session 11: Is there hope?
Lindsay Grayson:Will we have to rely on clean hands or is there hope in revitalizing the antibiotic pipeline?
1